Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 11/20 | 0.69 |
| ▸ | NPY2R | P49146 | 1/20 | 0.62 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.61 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10719616 | 0.90 | KCNH2 (0.58) | KCNH2MEN1NPY2RPAX8KMT2A | |
| SCHEMBL16307518 | 0.89 | KCNH2 (0.72) | KCNH2MEN1PAX8CYP2J2KMT2A | |
| SCHEMBL16307525 | 0.89 | KCNH2 (0.69) | KCNH2MEN1NPY2RPAX8CYP2J2 | |
| SCHEMBL10460762 | 0.86 | KCNH2 (0.86) | KCNH2MEN1PAX8CYP2J2KMT2A | |
| Fumaric Acid SCHEMBL10555655 | 0.86 | KCNH2 (0.54) | KCNH2MEN1NPY2RPAX8KMT2A | |
| SCHEMBL16307521 | 0.85 | KCNH2 (0.66) | KCNH2MEN1PAX8CYP2J2 | |
| SCHEMBL17023781 | 0.84 | KCNH2 (0.79) | KCNH2MEN1PAX8CYP2J2KMT2A | |
| SCHEMBL16291233 | 0.83 | KCNH2 (0.80) | KCNH2MEN1PAX8CYP2J2KMT2A | |
| SCHEMBL16307892 | 0.83 | KCNH2 (0.80) | KCNH2MEN1PAX8CYP2J2KMT2A | |
| SCHEMBL16307506 | 0.83 | KCNH2 (0.80) | KCNH2MEN1PAX8CYP2J2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212180-B2 | Menin-MLL inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212180-B2 | Menin-MLL inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140371239-A1 | MENIN-MLL INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-18 | — | — | US | disclosed |
| US-20140371239-A1 | MENIN-MLL INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371239-A1 | MENIN-MLL INHIBITORS AND METHODS OF USE THEREOF | MLLT1, MEN1, BMI1 | KCNH2 3751/4885MEN1 2/4885NPY2R 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.